Skip to content

A pilot study evaluating the safety and efficacy of suprachoroidal stent implantation in eyes with primary angle closure

A pilot study evaluating the safety and efficacy of suprachoroidal stent implantation in eyes with primary angle closure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-16008476
Enrollment
Unknown
Registered
2016-05-09
Start date
2016-05-11
Completion date
Unknown
Last updated
2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eyes with primary angle closure

Interventions

One cohort:Investigating the IOP lowering effect and the safety profile iStent Supra implantation in Chinese eyes with PAC or PACG, twelve months

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. PAC or PACT Chinese patients who are 18 years of age or above; 2. The trabecular meshwork is not visible for more than 180 degree on dark room gonioscopy; 3. IOP >22mmHg; 4. Without secondary causes of angle closure identified. PACG is diagnosed in eyes with PAC with evidence of glaucomatous optic disc damage (i.e. narrowing of neuroretinal rim, thinning of retinal nerve fiber layer, optic disc excavation with or without corresponding visual field defects); 5. A clear view of the angle at the intended implantation site, via gonioscopy at the screening visit and again at the operative exam.

Exclusion criteria

Exclusion criteria: 1. Peripheral anterior synechiae more than 180 degree at the nasal side; 2. Visual acuity worse than 6/60, pseudophakic, phakic with cataractous lens expected to require cataract surgery within 12 months of the screening exam; 3. The presence of advanced visual field defects with mean deviation (MD) <-18 dB; 4. Chronic or recurrent uveitis; 5. Pregnancy.

Design outcomes

Primary

MeasureTime frame
IOP reduction from preoperative IOP at 12 months of follow-up.;

Secondary

MeasureTime frame
Investigate the side effect of iStent.;

Countries

China

Contacts

Public ContactDr. Leung Kai Shun Christopher

The Chinese University of Hong Kong

cksleung@cuhk.edu.hk+852 2762 3080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026